SCHEMBL5577774

SCHEMBL5577774

COc1ccc(CN2CCN(c3ccccc3CNC(=O)c3cccc(Cl)c3C)CC2C)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 2/20 0.43
DRD2 P14416 4/20 0.41
DRD3 P35462 4/20 0.41
DRD4 P21917 3/20 0.41
TMEM97 Q5BJF2 2/20 0.41
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
APEX1 P27695 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
SPTLC2 O15270 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577636 0.88 LMNA (0.46) LMNAHPGDALDH1A1APEX1
SCHEMBL5577387 0.88 LMNA (0.43) LMNAHPGDKMT2ADRD3S1PR1
SCHEMBL5577489 0.87 MT-CO2 (0.48) LMNAKMT2ADRD2DRD3MEN1
SCHEMBL5577988 0.87 LMNA (0.47) LMNAHPGDAPEX1TSHR
SCHEMBL5577871 0.86 DRD2 (0.48) LMNADRD2DRD3DRD4GAA
SCHEMBL5577655 0.85 S1PR1 (0.45) LMNAHPGDKMT2ADRD2DRD3
SCHEMBL5577517 0.84 KDM4E (0.52) KMT2ADRD2DRD3DRD4TMEM97
SCHEMBL5577915 0.84 LMNA (0.44) LMNAHPGDDRD3KDM4EAPEX1
SCHEMBL5577758 0.83 LMNA (0.41) LMNAHPGDALDH1A1APEX1
SCHEMBL5577614 0.83 LMNA (0.40) LMNAHPGDS1PR1S1PR5APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-22 US disclosed
EP-1616862-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof HLA-DRB1, MIF, HLA-C LMNA 4819/4885HPGD 855/4885KMT2A 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.